Nasdaq:ADPTPublished
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies SEATTLE, Nov.
